Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Hugo Rank Gene description measured expected final
Results: HTML CSV LaTeX
Showing element 2002 to 2051 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
final\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NLK\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1701\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NEMO-LIKE KINASE; LIKELY ORTHOLOG OF MOUSE NEMO LIKE KINASE. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.210207\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.883788\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.237847764\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NME2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2010\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOSIDE DIPHOSPHATE KINASE A (EC 2.7.4.6) (NDK A) (NDP KINASE A) (TUMOR METASTATIC PROCESS-ASSOCIATED PROTEIN) (METASTASIS INHIBITION FACTOR NM23) (NM23-H1). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.494361\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.14316\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.230669199\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NME2P1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2011\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
PUTATIVE NUCLEOSIDE DIPHOSPHATE KINASE (EC 2.7.4.6) (NDK) (NDP KINASE). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.480816\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.08449\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.230663616\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NME3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2065\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOSIDE DIPHOSPHATE KINASE 3 (EC 2.7.4.6) (NDK 3) (NDP KINASE 3) (NM23-H3) (DR-NM23). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.366443\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.59695\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.229464291\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NMNAT3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1682\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE 3; PYRIDINE NUCLEOTIDE ADENYLYLTRANSFERASE 3. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.192536\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.808409\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.238166572\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOB1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1532\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NIN ONE BINDING PROTEIN; ADENOCARCINOMA ANTIGEN RECOGNIZED BY T LYMPHOCYTES 4. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0805704\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.332683\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.2421837\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOC3L\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1334\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
AD24 PROTEIN. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.290237\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.18321\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.24529627\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOC4L\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1507\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.511781\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.10953\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.242604277\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOL1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1565\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
PROLIFERATING-CELL NUCLEOLAR ANTIGEN P120 (PROLIFERATION-ASSOCIATED NUCLEOLAR PROTEIN P120). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.714168\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.96197\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.241112503\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOL10\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1416\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.651969\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.67215\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.243986677\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\parbox{\wcA}{\vspace{3pt}\noindent
NOL14\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1483\vspace{3pt}}&&\parbox{\wcD}{\vspace{3pt}\noindent
0.54526\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.24437\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.242945682\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOL5A\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1523\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOLAR PROTEIN NOP56 (NUCLEOLAR PROTEIN 5A). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.66215\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.73239\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.242333635\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOL6\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1267\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOLAR RNA-ASSOCIATED PROTEIN ALPHA ISOFORM. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.966893\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
3.91912\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.246711762\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOLA1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
256\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
"NUCLEOLAR PROTEIN FAMILY A, MEMBER 1; GAR1 PROTEIN. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.11305\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.363171\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.311285868\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOLA2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1714\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
"NUCLEOLAR PROTEIN FAMILY A, MEMBER 2; COMPONENT OF THE H/ACA SNORNP. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0909039\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.382985\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.237356293\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NONO\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1676\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
"54 KDA NUCLEAR RNA- AND DNA-BINDING PROTEIN (P54(NRB)) (P54NRB) (55 KDA NUCLEAR PROTEIN) (NMT55) (NON-POU DOMAIN-CONTAINING OCTAMER- BINDING PROTEIN) (DNA-BINDING P52/P100 COMPLEX, 52 KDA SUBUNIT). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.201833\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.847008\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.238289367\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOSTRIN\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1730\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NOSTRIN. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.02137\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.0901539\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.237039108\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NOVA1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1208\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
RNA-BINDING PROTEIN NOVA-1 (NEURO-ONCOLOGICAL VENTRAL ANTIGEN 1) (ONCONEURAL VENTRAL ANTIGEN-1) (PARANEOPLASTIC RI ANTIGEN) (VENTRAL NEURON-SPECIFIC PROTEIN 1). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.107742\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.434244\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.248113964\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NPC2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
272\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
EPIDIDYMAL SECRETORY PROTEIN E1 PRECURSOR (NIEMANN-PICK DISEASE TYPE C2 PROTEIN) (EPI-1) (HE1) (EPIDIDYMAL SECRETORY PROTEIN 14.6) (ESP14.6). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.115432\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.377878\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.305474254\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NPEPPS\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2270\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
PUROMYCIN-SENSITIVE AMINOPEPTIDASE (EC 3.4.11.-) (PSA). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0267797\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.120229\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.222739106\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NPLOC4\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
446\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.260039\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.939933\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.276656953\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR1H2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1582\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
OXYSTEROLS RECEPTOR LXR-BETA (LIVER X RECEPTOR BETA) (NUCLEAR ORPHAN RECEPTOR LXR-BETA) (UBIQUITOUSLY-EXPRESSED NUCLEAR RECEPTOR) (NUCLEAR RECEPTOR NER). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0824164\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.34213\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.240892059\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR1H3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1579\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
OXYSTEROLS RECEPTOR LXR-ALPHA (LIVER X RECEPTOR ALPHA) (NUCLEAR ORPHAN RECEPTOR LXR-ALPHA). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.110811\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.460002\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.240892431\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR2C1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1006\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR TR2. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.211877\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.831867\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.254700571\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR2E1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1007\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR NR2E1 (NUCLEAR RECEPTOR TLX) (TAILLESS HOMOLOG) (TLL) (HTLL). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.280845\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.10266\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.254697731\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR4A1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2777\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR HMR (EARLY RESPONSE PROTEIN NAK1) (TR3 ORPHAN RECEPTOR). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.508993\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.52853\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.201299965\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR4A2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2775\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR NURR1 (IMMEDIATE-EARLY RESPONSE PROTEIN NOT) (TRANSCRIPTIONALLY INDUCIBLE NUCLEAR RECEPTOR). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.603026\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.99447\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.201379877\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR4A3\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2776\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEAR HORMONE RECEPTOR NOR-1 (NEURON-DERIVED ORPHAN RECEPTOR 1) (MITOGEN INDUCED NUCLEAR ORPHAN RECEPTOR). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.515632\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
2.56143\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.201306302\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NR6A1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
907\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ORPHAN NUCLEAR RECEPTOR NR6A1 (GERM CELL NUCLEAR FACTOR) (GCNF) (RETINOID RECEPTOR-RELATED TESTIS SPECIFIC RECEPTOR) (RTR). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.196675\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.76137\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.258317244\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NRD1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
726\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NARDILYSIN PRECURSOR (EC 3.4.24.61) (N-ARGININE DIBASIC CONVERTASE) (NRD CONVERTASE) (NRD-C). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0787172\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.297409\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.26467659\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NSF\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1708\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
VESICLE-FUSING ATPASE (EC 3.6.4.6) (VESICULAR-FUSION PROTEIN NSF) (N- ETHYLMALEIMIDE SENSITIVE FUSION PROTEIN) (NEM-SENSITIVE FUSION PROTEIN). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.15883\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.66831\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.23765917\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NSFL1C\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
675\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
P47 PROTEIN ISOFORM A. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0978055\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.367477\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.266154072\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NSMCE4A\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
3139\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.64337\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
25.135\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.065381739\vspace{3pt}}\\\cline{1-2}\cline{4-6}
\parbox{\wcA}{\vspace{3pt}\noindent
NSUN2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2400\vspace{3pt}}&&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.100955\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.460869\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.219053571\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
NSUN5\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2399\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
WILLIAMS BEUREN SYNDROME CRITICAL REGION 20A ISOFORM 2; NOL1/NOP2/SUN GENE FAMILY MEMBER; WILLIAMS-BEUREN SYNDROME CRITICAL REGION PROTEIN 20 COPY A; WILLIAMS BEUREN SYNDROME CHROMOSOME REGION 20. \vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NSUN5B\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2402\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
WILLIAMS BEUREN SYNDROME CHROMOSOME REGION 20C ISOFORM 1. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0859883\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.392545\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.219053357\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUAK1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1004\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
PROBABLE SERINE/THREONINE-PROTEIN KINASE KIAA0537 (EC 2.7.1.-). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.139695\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.54802\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.25490858\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUAK2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
998\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.115392\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.452671\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.254913613\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUBP1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2942\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOTIDE-BINDING PROTEIN 1 (NBP 1). \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.0819552\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.528466\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
0.155081311\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
NUBP2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2943\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOTIDE BINDING PROTEIN 2 (NBP 2). \vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUCB1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2212\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOBINDIN 1 PRECURSOR (CALNUC). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0240186\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.106724\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.225053409\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUCB2\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2210\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOBINDIN 2 PRECURSOR (DNA-BINDING PROTEIN NEFA). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0283406\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.125928\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.225053999\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUDT12\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1959\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE MOTIF 12. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0196941\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.085173\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.231224684\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUDT21\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
359\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
"CLEAVAGE AND POLYADENYLATION SPECIFIC FACTOR 5, 25 KD SUBUNIT; PRE-MRNA CLEAVAGE FACTOR IM (25KD); PRE-MRNA CLEAVAGE FACTOR IM, 25KD SUBUNIT. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.288916\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
1.0267\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.281402552\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUFIP1\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
398\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEAR FRAGILE X MENTAL RETARDATION PROTEIN INTERACTING PROTEIN 1; NUCLEAR FRAGILE X MENTAL RETARDATION INTERCATING PROTEIN 1; NUCLEAR FRAGILE X MENTAL RETARDATION PROTEIN-INTERACTING PROTEIN 1. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.0673151\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.241784\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.278410068\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUMB\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2652\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUMB PROTEIN HOMOLOG (H-NUMB) (PROTEIN S171). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.130073\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.619508\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.209961776\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUMBL\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
2653\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUMB-LIKE PROTEIN (NUMB-R). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.122765\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.584702\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.209961656\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUP43\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1415\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOPORIN NUP43 (P42). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.149203\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.611499\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.243995493\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUP54\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
1480\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEOPORIN 54KDA; NUCLEOPORIN P54. \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.114912\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.472937\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.24297528\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
NUP88\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
310\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
NUCLEAR PORE COMPLEX PROTEIN NUP88 (NUCLEOPORIN NUP88) (88 KDA NUCLEAR PORE COMPLEX PROTEIN). \vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.251667\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.851392\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
0.295594744\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/